Skip To Main Content
Peder Rustøen Braadland on Muck Rack

Peder Rustøen Braadland

As seen in: Nature, JHEP Reports
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Peder Rustøen

Contact Peder Rustøen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Gut microbiota-derived imidazole propionate promotes primary sclerosing cholangitis via p38 signalling

|
By Antonio Molinaro, Peder Rustøen Braadland, Guido Carpino, Alba Carreras, Marios Nikolaidis, Katharina Beck, Ahmad Ali, Lars Bossen, Anna Frank, Annika Lundqvist, Brian Juran, Diletta Overi, Lei Geng, Henrik Mikael Reims, Ida Björk, Krzysztof Grzyb, Andreas Abildgaard, Trine Folseraas, Martin Cornillet, Laura Cristoferi, Marco Carbone, Vincenzo Cardinale, Marte L. Høivik, Adrian McCann, Per M Ueland, Mette Nåmdal Vesterhus, Tom H Karlsen, Henning Grønbæk, Eugenio Gaudio, Konstantinos N. Lazaridis, Annika Bergquist, Espen Melum, Fredrik Bäckhed, Johannes Roksund Hov, Petra Hanzely, Hólmfríður Helgadóttir, Bryan M. McCauley, Lise Katrine Engesæter, Sara K. V. Tjønnfjord
| Nature Verified
Abstract Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the bile ducts that can lead to biliary cancer and end-stage liver disease. PSC is associated with inflammatory bowel disease and an altered gut microbiota. However, the molecular mechanisms underlying gut–liver interactions in PSC remain poorly characterized. Here we show that the gut microbiota-derived metabolite imidazole propionate (ImP) is a disease driver in PSC.
Open in Who Shared Issue with article?

Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis

|
By Peder Rustøen Braadland, Inflammatory Diseases, Kai Markus Schneider, Annika Bergquist
| JHEP Reports Verified
Patients with PSC with suppressed synthesis of bile acids experience shorter liver transplantation-free survival Cholestasis-driven liver damage is believed to be a major cause of the complications of advanced PSC. We, therefore, evaluated whether circulating levels of C4 had an apparent association with liver transplantation-free survival and if it could improve prediction atop established risk prediction models in 2 independent populations with PSC, irrespective of UDCA use.
Open in Who Shared Issue with article?
See all 2 articles